Home » Newsletters » BioWorld Science

BioWorld Science

July 19, 2010

View Archived Issues

Studies refine CAD-106 treatment regimen

Phase I trial shows safety MABT-5102-A in patients with AD

New HPV DNA vaccine AcHERV-HP16/18L1 is immunogenic in vivo

Poly-ICR can block suppression of anti-HPV immune responses

Glenmark Pharmaceuticals claims new TRPV3 channel inhibitors

Array BioPharma discovers new DP2 receptor inhibitors

Schering discloses novel nicotinic acid receptor agonists

Chinese scientists identify novel protein kinase inhibitors

AD candidate RQ-9 improves memory and cognition in rodents

Canagliflozin improves glucose control in persons with type 2 diabetes

Renovo provides update on product pipeline

Vernalis and Biogen to replace vipadenant in Parkinson's disease program

Supernus begins phase IIa SPN-812 trial in adults with ADHD

Lantheus launches Definity ultrasound contrast imaging product in India

Biolipox presents novel PDE4/PDE7 inhibitors

Elusys and Lonza extend contract to produce Anthim for inhalation anthrax

Galapagos and Bristol University to develop agents for diabetes-associated chronic pain

Nitric Bio begins phase II trial of terbinafine/device combination in onychomycosis

GTC regains rights to recombinant antithrombin ATryn

Amgen's denosumab BLA receives FDA priority review status

Biomet acquires substantially all assets of Cytosol Laboratories

Cangene's option to license Maxygen's MAXY-G34 for ARS expires

FDA extends PDUFA date for Walter Chilcott's Actonel product

Novo Nordisk completes recruitment in A1chieve trial of insulin regimens

Evotec gains new alliances in acquisition of DeveloGen

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...